These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26318398)

  • 1. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis.
    Alvarez ML; Khosroheidari M; Eddy E; Done SC
    Atherosclerosis; 2015 Oct; 242(2):595-604. PubMed ID: 26318398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production.
    Dong J; He M; Li J; Pessentheiner A; Wang C; Zhang J; Sun Y; Wang WT; Zhang Y; Liu J; Wang SC; Huang PH; Gordts PL; Yuan ZY; Tsimikas S; Shyy JY
    JCI Insight; 2020 Dec; 5(23):. PubMed ID: 33119548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator.
    Jiang H; Zhang J; Du Y; Jia X; Yang F; Si S; Wang L; Hong B
    Atherosclerosis; 2015 Dec; 243(2):523-32. PubMed ID: 26523989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
    Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
    Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes.
    Xu Y; Gao J; Gong Y; Chen M; Chen J; Zhao W; Tan S
    Atherosclerosis; 2020 Mar; 297():111-119. PubMed ID: 32109664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE.
    Ason B; van der Hoorn JW; Chan J; Lee E; Pieterman EJ; Nguyen KK; Di M; Shetterly S; Tang J; Yeh WC; Schwarz M; Jukema JW; Scott R; Wasserman SM; Princen HM; Jackson S
    J Lipid Res; 2014 Nov; 55(11):2370-9. PubMed ID: 25258384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in mice.
    Goedeke L; Rotllan N; Ramírez CM; Aranda JF; Canfrán-Duque A; Araldi E; Fernández-Hernando A; Langhi C; de Cabo R; Baldán Á; Suárez Y; Fernández-Hernando C
    Atherosclerosis; 2015 Dec; 243(2):499-509. PubMed ID: 26520906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.
    Levy E; Ben Djoudi Ouadda A; Spahis S; Sane AT; Garofalo C; Grenier É; Emonnot L; Yara S; Couture P; Beaulieu JF; Ménard D; Seidah NG; Elchebly M
    Atherosclerosis; 2013 Apr; 227(2):297-306. PubMed ID: 23422832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.
    Qian YW; Schmidt RJ; Zhang Y; Chu S; Lin A; Wang H; Wang X; Beyer TP; Bensch WR; Li W; Ehsani ME; Lu D; Konrad RJ; Eacho PI; Moller DE; Karathanasis SK; Cao G
    J Lipid Res; 2007 Jul; 48(7):1488-98. PubMed ID: 17449864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
    Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
    FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H; Rashid S; Fazio S
    Atherosclerosis; 2015 Feb; 238(2):264-70. PubMed ID: 25544176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.
    DeVay RM; Yamamoto L; Shelton DL; Liang H
    PLoS One; 2015; 10(4):e0125127. PubMed ID: 25905719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.
    Ferri N; Tibolla G; Pirillo A; Cipollone F; Mezzetti A; Pacia S; Corsini A; Catapano AL
    Atherosclerosis; 2012 Feb; 220(2):381-6. PubMed ID: 22176652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression.
    Miranda MX; van Tits LJ; Lohmann C; Arsiwala T; Winnik S; Tailleux A; Stein S; Gomes AP; Suri V; Ellis JL; Lutz TA; Hottiger MO; Sinclair DA; Auwerx J; Schoonjans K; Staels B; Lüscher TF; Matter CM
    Eur Heart J; 2015 Jan; 36(1):51-9. PubMed ID: 24603306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.